Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965716 · ClinicalTrials.gov registry record · Phase 2
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
A Phase 2 study of Unresectable Melanoma and Recurrent Melanoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 20
- Study locations
NCT02965716: Active Phase 2 study of Unresectable Melanoma and Recurrent Melanoma, sponsored by National Cancer Institute (NCI).
NCT02965716 is a Phase 2 study of Unresectable Melanoma and Recurrent Melanoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants, below the 140-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02965716, a Phase 2 study of Unresectable Melanoma and Recurrent Melanoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
Primary Outcome
Number of participants with a complete response, defined as the disappearance of all target and non-target lesions, or partial response, defined as a greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable legions. ORR is measured using RECIST 1.1 guidelines.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Talimogene Laherparepvec
Study Locations (20)
Michigan
- Henry Ford Cancer Institute-Downriver - Brownstown
- Henry Ford Macomb Hospital-Clinton Township - Clinton Township
- Henry Ford Hospital - Detroit
- Allegiance Health - Jackson
- Henry Ford West Bloomfield Hospital - West Bloomfield
California
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Keck Medical Center of USC Pasadena - Pasadena
Ohio
- University of Cincinnati Cancer Center-UC Medical Center - Cincinnati
- Ohio State University Comprehensive Cancer Center - Columbus
- University of Cincinnati Cancer Center-West Chester - West Chester
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Arizona
- CTCA at Western Regional Medical Center - Goodyear
Illinois
- Loyola University Medical Center - Maywood
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
Kansas
- University of Kansas Hospital-Westwood Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2026-11-04 |
| Phase | Phase 2 |
What the registry record for NCT02965716 still lists
NCT02965716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 140-participant average among 24 other Unresectable Melanoma trials with a reported enrollment target (69% lower).
The record links to 8 conditions, with Unresectable Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02965716 names 20 study sites across 11 states, led by Michigan, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT02965716 about?
NCT02965716 is a clinical study titled "Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma". This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways a...
What is the current status of trial NCT02965716?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2018-06-05. Estimated completion is 2026-11-04.
What conditions does trial NCT02965716 study?
This clinical trial studies the following conditions: Unresectable Melanoma, Recurrent Melanoma, Advanced Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IIIC Cutaneous Melanoma AJCC v7.
What interventions are being tested in trial NCT02965716?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Talimogene Laherparepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT02965716?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02965716 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02965716's enrollment target sits among peer trials
43 19th of 24 higher than 6 of 24 other Unresectable Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unresectable Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
RECRUITING · Phase 2
-
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
RECRUITING · Phase 2
-
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RECRUITING · Phase 2
-
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI